In this episode, Rachel Cole, PharmD, explores the evolving landscape of medications for HIV pre-exposure prophylaxis (PrEP), spotlighting lenacapavir (Yeztugo)—a newly approved long-acting injectable option given just twice yearly. She walks through how it compares to oral therapies like Truvada and Descovy, plus other injectables such as cabotegravir. Rachel also offers practical guidance on identifying candidates for HIV PrEP, navigating lab requirements, and managing side effects.&n...
All content for Clinical Capsules is the property of TRC Healthcare and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In this episode, Rachel Cole, PharmD, explores the evolving landscape of medications for HIV pre-exposure prophylaxis (PrEP), spotlighting lenacapavir (Yeztugo)—a newly approved long-acting injectable option given just twice yearly. She walks through how it compares to oral therapies like Truvada and Descovy, plus other injectables such as cabotegravir. Rachel also offers practical guidance on identifying candidates for HIV PrEP, navigating lab requirements, and managing side effects.&n...
New Twists to Old Meds: Fresh Formulations of Losartan, Minocycline, and More
Clinical Capsules
19 minutes
3 months ago
New Twists to Old Meds: Fresh Formulations of Losartan, Minocycline, and More
In this episode, TRC Healthcare editor, Vickie Danaher, PharmD, discusses recently approved drug formulations that bring fresh options—and new challenges—to the pharmacy counter. From Arbli, the first ready-to-use losartan suspension, to Emrosi, a low-dose minocycline for rosacea, and Opipza, an oral film version of aripiprazole, we’ll walk through what makes each product unique and what pharmacy teams should watch for. We also cover HemiClor, a 12.5 mg chlorthalidone tablet that may he...
Clinical Capsules
In this episode, Rachel Cole, PharmD, explores the evolving landscape of medications for HIV pre-exposure prophylaxis (PrEP), spotlighting lenacapavir (Yeztugo)—a newly approved long-acting injectable option given just twice yearly. She walks through how it compares to oral therapies like Truvada and Descovy, plus other injectables such as cabotegravir. Rachel also offers practical guidance on identifying candidates for HIV PrEP, navigating lab requirements, and managing side effects.&n...
